These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34231124)

  • 1. Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience.
    Bardasi C; Spallanzani A; Benatti S; Spada F; Laffi A; Antonuzzo L; Lavacchi D; Marconcini R; Ferrari M; Rimini M; Caputo F; Santini C; Cerma K; Casadei-Gardini A; Andrikou K; Salati M; Bertolini F; Fontana A; Dominici M; Luppi G; Gelsomino F
    Endocrine; 2021 Dec; 74(3):707-713. PubMed ID: 34231124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
    Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
    BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.
    Bongiovanni A; Liverani C; Foca F; Bergamo F; Leo S; Pusceddu S; Gelsomino F; Brizzi MP; Di Meglio G; Spada F; Tamberi S; Lolli I; Cives M; Marconcini R; Pucci F; Berardi R; Antonuzzo L; Badalamenti G; Santini D; Recine F; Vanni S; Tebaldi M; Severi S; Rudnas B; Nanni O; Ranallo N; Crudi L; Calabrò L; Ibrahim T
    Eur J Cancer; 2024 Sep; 208():114129. PubMed ID: 39002347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
    Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
    Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
    Craig Z; Swain J; Batman E; Wadsley J; Reed N; Faluyi O; Cave J; Sharma R; Chau I; Wall L; Lamarca A; Hubner R; Mansoor W; Sarker D; Meyer T; Cairns DA; Howard H; Valle JW; McNamara MG
    BMJ Open; 2020 Feb; 10(2):e034527. PubMed ID: 32029495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
    Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
    Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.
    Hadoux J; Malka D; Planchard D; Scoazec JY; Caramella C; Guigay J; Boige V; Leboulleux S; Burtin P; Berdelou A; Loriot Y; Duvillard P; Chougnet CN; Déandréis D; Schlumberger M; Borget I; Ducreux M; Baudin E
    Endocr Relat Cancer; 2015 Jun; 22(3):289-98. PubMed ID: 25770151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
    Hadoux J; Afchain P; Walter T; Tougeron D; Hautefeuille V; Monterymard C; Lorgis V; Thuillier F; Baudin E; Scoazec JY; Lepage C; Desgrippes R
    Dig Liver Dis; 2021 Jul; 53(7):824-829. PubMed ID: 33994125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.
    Sugiyama K; Shiraishi K; Sato M; Nishibori R; Nozawa K; Kitagawa C
    J Gastrointest Cancer; 2021 Sep; 52(3):947-951. PubMed ID: 32918273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.
    Lu ZH; Li J; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li Y; Shen L
    Med Oncol; 2013; 30(3):664. PubMed ID: 23864251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
    Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
    Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
    Zhang P; Li J; Li J; Zhang X; Zhou J; Wang X; Peng Z; Shen L; Lu M
    Cancer; 2020 May; 126 Suppl 9(Suppl 9):2086-2092. PubMed ID: 32293725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma.
    Yeung HM; Sreekrishnanilayam K; Meeker C; Deng M; Agrawal S; Abdullah H; Vijayvergia N
    J Gastrointest Cancer; 2023 Mar; 54(1):73-79. PubMed ID: 35006522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
    Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
    J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.
    McGarrah PW; Leventakos K; Hobday TJ; Molina JR; Finnes HD; Westin GF; Halfdanarson TR
    Pancreas; 2020 Apr; 49(4):529-533. PubMed ID: 32282766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma.
    Apostolidis L; Bergmann F; Jäger D; Winkler EC
    Cancer Med; 2016 Sep; 5(9):2261-7. PubMed ID: 27456539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
    Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
    Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
    Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
    Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.